Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4AXPT)

• Drug Name: VMD-928 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 91826737
  TTD Drug ID: DM4AXPT

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[2]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[3]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[5]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[6]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[7]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[9]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[1]

References

• [1] ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [8] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [9] National Cancer Institute Drug Dictionary (drug id 747694).
• [10] National Cancer Institute Drug Dictionary (drug id 766123).